MRC & Stratified Medicine
The MRC’s Stratified Medicine Initiative forms a major part of the MRC's research strategy, with a commitment to invest £60million between 2010 and 2014. The overall aim is to improve our understanding of how to tailor treatments and interventions to the individual needs of people living with a wide range of diseases and conditions. The MRC is coordinating its activities in this area with the Technology Strategy Board, the National Institute of Health Research, the UK Health Departments, Cancer Research UK and Arthritis Research UK.
The initiative's first call was held in 2012 and sought to help develop and fund UK-wide research consortia each focussed on a specific disease with an existing therapy or therapies which produced different responses in patients. STOP-HCV was one of the four consortia funded through this call.
Dr Jonathan Pearce joined the MRC’s Translational Research Team in 2008. Prior to joining the MRC, Jonathan undertook academic research at Cambridge, Oxford and Toronto, followed by roles in life sciences venture capital and strategic consulting. Jonathan manages the Regenerative Medicine Research Committee Scheme, which supports the translation of basic and clinical research findings towards the clinic, and the Council’s Stratified Medicine initiative